| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 527,978 | 72,086 | ||
| Prepaid expenses and other current assets | 298,192 | 378,749 | ||
| Vendor deposits | 169,363 | 98,234 | ||
| Total current assets | 995,533 | 549,069 | ||
| Vendor deposit | - | 69,477 | ||
| In-process research and development | - | 18,647,903 | ||
| Deferred offering costs | 44,727 | 374,662 | ||
| Total assets | 1,040,260 | 19,641,111 | ||
| Accounts payable | 9,805,129 | 9,774,230 | ||
| Accrued expenses and other current liabilities | 2,960,698 | 2,915,448 | ||
| Total current liabilities | 12,765,827 | 12,689,678 | ||
| Deferred tax liability | - | 851,659 | ||
| Total liabilities | 12,765,827 | 13,541,337 | ||
| Preferred stock-Series BPreferred Stock | 1 | 1 | ||
| Preferred stock-Series APreferred Stock | - | 0 | ||
| Common stock | 809 | 487 | ||
| Additional paid-in-capital | 125,187,156 | 123,207,260 | ||
| Accumulated deficit | -136,906,365 | -117,100,806 | ||
| Treasury stock, at cost, 7 shares at september 30, 2025 and december 31, 2024 | 7,168 | 7,168 | ||
| Total stockholders (deficit) equity | -11,725,567 | 6,099,774 | ||
| Total liabilities and stockholders (deficit) equity | 1,040,260 | 19,641,111 | ||
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)